IndraLab

Statements

Diosgenin inhibits RELA. 7 / 8
1 | 7
reach
"Diosgenin markedly inhibited the activation of NF-κB p65/p50, p38, and the production of inducible nitric oxide synthase (iNOS) in LPS-induced THP-1 cells, implicating its potential in the treatment of acute lung injury.109 Diosgenin has demonstrated considerable anticancer potential by targeting many oncogenic elements within cell signaling pathways related to lung carcinogenesis."
40160969
reach
"Diosgenin Reduces Acute Kidney Injury and Ameliorates the Progression to Chronic Kidney Disease by Modifying the NOX4/p65 Signaling Pathways."
39074384
reach
"Both diosgenin at three doses of 0.1, 1.0, 10 mg/kg and BBR 50 mg/kg exerted inhibition on NF-κB p50 and p65, especially diosgenin 10 mg/kg significantly suppressed NF-κB p50 activation with inhibitio[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
23246979
reach
"Diosgenin down-regulates NF-kappaB p65 and p50 and p38MAPK pathways and attenuates acute lung injury induced by lipopolysaccharide in mice."
25246240
reach
"Both diosgenin and BBR exhibited an inhibition on NF-κB p50/p65, p38MAPK and iNOS, especially diosgenin significantly suppressed iNOS activation with inhibition rate as 79.3%."
23246979
reach
"Correction to "Diosgenin Reduces Acute Kidney Injury and Ameliorates the Progression to Chronic Kidney Disease by Modifying the NOX4/p65 Signaling Pathways"."
39425655
reach
"Co-treatment of DG with cisplatin enhanced cellular cytotoxicity by elevating ROS levels, generating oxidative DNA damage, and diminishing cellular antioxidant defense, thus resulting in significant activation of death in tumor cells.108 Diosgenin inhibited the NF-κB p65/p50 and p38MAPK pathways, mitigating acute lung damage caused by lipopolysaccharide in mice."
40160969